LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more
LungLife AI Inc (LLAI) - Total Assets
Latest total assets as of June 2024: GBX9.06 Million GBX
Based on the latest financial reports, LungLife AI Inc (LLAI) holds total assets worth GBX9.06 Million GBX as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LungLife AI Inc - Total Assets Trend (2018–2023)
This chart illustrates how LungLife AI Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LungLife AI Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
LungLife AI Inc's total assets of GBX9.06 Million consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 28.6% |
| Accounts Receivable | GBX175.00K | 1.8% |
| Inventory | GBX-175.00K | -1.8% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX5.82 Million | 61.1% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how LungLife AI Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LungLife AI Inc's current assets represent 34.7% of total assets in 2023, a decrease from 50.4% in 2018.
- Cash Position: Cash and equivalents constituted 28.6% of total assets in 2023, down from 30.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 61.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 61.1% of total assets.
LungLife AI Inc Competitors by Total Assets
Key competitors of LungLife AI Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
LungLife AI Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LungLife AI Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - LungLife AI Inc is currently not profitable relative to its asset base.
LungLife AI Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.83 | 4.08 | 0.15 |
| Quick Ratio | 2.83 | 4.08 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX1.92 Million | GBX 4.41 Million | GBX -3.86 Million |
LungLife AI Inc - Advanced Valuation Insights
This section examines the relationship between LungLife AI Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -36.6% |
| Total Assets | GBX9.52 Million |
| Market Capitalization | $158.54 USD |
Valuation Analysis
Below Book Valuation: The market values LungLife AI Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LungLife AI Inc's assets decreased by 36.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LungLife AI Inc (2018–2023)
The table below shows the annual total assets of LungLife AI Inc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | GBX9.52 Million | -36.60% |
| 2022-12-31 | GBX15.02 Million | -31.62% |
| 2021-12-31 | GBX21.97 Million | +2.07% |
| 2020-12-31 | GBX21.52 Million | +1142.03% |
| 2019-12-31 | GBX1.73 Million | +140.20% |
| 2018-12-31 | GBX721.36K | -- |